Allergan makes deal with Amneal over its Namenda XR generic

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Allergan makes deal with Amneal over its Namenda XR generic

Genéricos/Novedades | Posted 09/10/2015 0 Post your comment

Allergan has gained some breathing space for the extended-release version of its blockbuster Alzheimer’s disease treatment Namenda XR (memantine XR) after making a deal to delay generics entry for more than four years.

Allergan announced on 10 September 2015 that its subsidiary Forest Laboratories (Forest) had made a deal with US generics maker Amneal Pharmaceuticals (Amneal) regarding the latter’s generic version of the drug. The deal comes after Forest, along with Merz Pharma (Merz) and Adamas Pharmaceuticals (Adamas), initiated patent litigation in response to Amneal’s abbreviated new drug application (ANDA) seeking approval to market generic extended-release memantine [1].

Amneal is believed to be the first applicant to file an ANDA containing a paragraph IV certification regarding Namenda XR, which would give Amneal 180-days marketing exclusivity. The deal means that Amneal can start marketing its generic version from 31 January 2020, following approval of its ANDA by the US Food and Drug Administration (FDA). Alternatively, Amneal can wait until 31 January 2021 and launch an authorized generic drug.

The US patent on the immediate-release version of Namenda (Namenda IR) expired in January 2015. Generics giant Dr Reddy’s Laboratories launched its generic of memantine in July 2015 [2], which was closely followed by a number of other generics makers.

The patent on the newer extended-release version of Namenda (Namenda XR) only expires in 2025. However, this is not the end of the story. Forest Laboratories has also filed a lawsuit against generics makers Sun Pharma Global, Teva Pharmaceuticals USA and Wockhardt Bio, all of whom have filed ANDAs with FDA seeking approval to market generics of Namenda XR [3].

References
1. GaBI Online - Generics and Biosimilars Initiative. Forest Labs files lawsuit to stop generic memantine [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Oct 9]. Available from: www.gabionline.net/Generics/News/Forest-Labs-files-lawsuit-to-stop-generic-memantine
2. GaBI Online - Generics and Biosimilars Initiative. Alzheimer generic launched in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Oct 9]. Available from: www.gabionline.net/Generics/News/Alzheimer-generic-launched-in-the-US
3. GaBI Online - Generics and Biosimilars Initiative. Forest Labs files lawsuit to stop generic memantine [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Oct 9]. Available from: www.gabionline.net/Generics/News/Forest-Labs-files-lawsuit-to-stop-generic-memantine

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Allergan,US FDA